BioLineRx Ltd (NASDAQ:BLRX) Q2 2019 Earnings Conference Call - Final Transcript
Aug 06, 2019 • 10:00 am ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2019 Conference Call. All participants are at present in a listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. (Operator Instructions)
I would now like to turn call over to Timothy McCarthy of LifeSci Advisors to read the Safe Harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements.
All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in BioLineRx's annual report on Form 20-F, quarterly reports filed in the 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed.
Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.
At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.
Thank you, Tim, and good morning, everyone, and thank you for joining us on our second quarter earnings conference call today. Earlier this morning, we issued our Q2 earnings press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K.
I will begin with the brief review of our programs and activities and enumerate our major target milestones over the next several quarters. And then, Mali Zeevi, our Chief Financial Officer, will provide a short discussion of our financial results. We will then open up the call to your questions. Also during the call for Q&A, are Abi Vainstein, our Vice President, Clinical Development; and Ella Sorani, our Vice President, Research and Development.
During the second quarter, we continued to aggressively advance our lead therapeutic candidates BL-8040 and AGI-134, both of which we're developing for the treatment of multiple cancer indications. Beginning with BL-8040, which we are evaluating in a number of Phase 2 and Phase 3 clinical trials in multiple oncology indications, including pancreatic cancer, acute myeloid leukemia and stem cell mobilization for multiple myeloma patients.
We see BL-8040 as a broad platform molecule that can be combined with a wide array of different molecules to potentially treat a broad range of cancers at various stages of disease. Recall that BL-8040 has been granted FDA orphan drug designation in all three main therapeutic areas previously mentioned, pancreatic cancer, AML and stem cell mobilization. We view these designations as confirmation